Regulus Therapeutics Inc.
RGLS
Rangering i aksjer
#17332
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aksjekurs
$8.16
Sist synkronisert: 2025-06-26
Markedsverdi
$234.57M
Endring (1 dag)
0.00%
Endring (1 år)
-88.86%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)
Kategori
Healthcare
Historikk for aksjesplitt for Regulus Therapeutics Inc. (RGLS)
Aksjen Regulus Therapeutics Inc. (symbol: RGLS) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én RGLS-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 RGLS-aksjer.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én RGLS-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 RGLS-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
